Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 9/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 4/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1670184 | 1.00 | CALCRL (0.49) | CALCRLADRB2CYP3A4HTR1ASLC6A2 | |
| SCHEMBL1672795 | 1.00 | CALCRL (0.49) | CALCRLADRB2CYP3A4HTR1ASLC6A2 | |
| SCHEMBL16615981 | 1.00 | CALCRL (0.49) | CALCRLADRB2CYP3A4HTR1ASLC6A2 | |
| SCHEMBL829734 | 1.00 | CALCRL (0.49) | CALCRLADRB2CYP3A4HTR1ASLC6A2 | |
| SCHEMBL16624591 | 0.88 | CALCRL (0.38) | CALCRLADRB2CYP3A4HTR1ASLC6A2 | |
| SCHEMBL16616000 | 0.88 | CALCRL (0.38) | CALCRLADRB2CYP3A4HTR1ASLC6A2 | |
| SCHEMBL16615999 | 0.88 | CALCRL (0.38) | CALCRLADRB2CYP3A4HTR1ASLC6A2 | |
| SCHEMBL15674334 | 0.87 | CALCRL (0.48) | CALCRLADRB2CYP3A4HTR1ASLC6A2 | |
| SCHEMBL1670444 | 0.87 | CALCRL (0.38) | CALCRLADRB2CYP3A4HTR1ASLC6A2 | |
| SCHEMBL15674335 | 0.87 | CALCRL (0.48) | CALCRLADRB2CYP3A4HTR1ASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3254681-B1 | N-(5S,6S,9R)-5-AMINO-6-(2,3-DIFLUOROPHENYL)-6,7,8,9-TETRAHYDRO-5H-CYCLOHEPTA[B]PYRIDIN-9-YL-4-(2-OXO-2,3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDIN-1-YL)PIPERIDINE-1-CARBOXYLATE SALT | BRISTOL MYERS SQUIBB CO (US) | 2019-06-19 | — | — | EP | disclosed |
| EP-2820016-B1 | N- (5S, 6S, 9R) - 5 -AMINO- 6 - (2, 3 - DIFLUOROPHENYL) -6, 7, 8, 9 - TETRAHYDRO - 5H - CYCLOHEPTA [B]PYRIDIN-9 -YL- 4 - (2 - OXO-2, 3 - DIHYDRO - 1H- IMIDAZO [4, 5 -B]PYRIDIN - 1 - YL) PIPERIDINE - 1 - CARBOXYLATE, HEMISULFATE SALT | BRISTOL MYERS SQUIBB CO (US) | 2017-08-02 | — | — | EP | disclosed |
| US-9227973-B2 | Pyridine CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150099771-A1 | PYRIDINE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-04-09 | — | — | US | disclosed |
| EP-2820016-A1 | N- (5S, 6S, 9R) - 5 -AMINO- 6 - (2, 3 - DIFLUOROPHENYL) -6, 7, 8, 9 - TETRAHYDRO - 5H - CYCLOHEPTA [B]PYRIDIN-9 -YL- 4 - (2 - OXO-2, 3 - DIHYDRO - 1H- IMIDAZO [4, 5 -B]PYRIDIN - 1 - YL) PIPERIDINE - 1 - CARBOXYLATE, HEMISULFATE SALT | Bristol-Myers Squibb Company (US) | 2015-01-07 | — | — | EP | disclosed |
| EP-2815749-A1 | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern | IP Gesellschaft für Management mbH (DE) | 2014-12-24 | — | — | EP | disclosed |
| US-8759372-B2 | N-(5S,6S,9R)-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-ctclohepta[b]Pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-carboxylate salt | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-24 | — | — | US | disclosed |
| EP-2488512-B1 | CGRP receptor antagonists | BRISTOL MYERS SQUIBB CO (US) | 2013-11-27 | — | — | EP | disclosed |
| WO-2013130402-A1 | N- (5S, 6S, 9R) - 5 -AMINO- 6 - (2, 3 - DIFLUOROPHENYL) -6, 7, 8, 9 - TETRAHYDRO - 5H - CYCLOHEPTA [B] PYRIDIN-9 -YL- 4 - (2 - OXO-2, 3 - DIHYDRO - 1H- IMIDAZO [4, 5 -B] PYRIDIN - 1 - YL) PIPERIDINE - 1 - CARBOXYLATE, HEMISULFATE SALT | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-09-06 | — | — | WO | disclosed |
| US-20130225636-A1 | N-(5S,6S,9R)-5-AMINO-6-(2,3-DIFLUOROPHENYL)-6,7,8,9-TETRAHYDRO-5H-CYCLOHEPTA[B]PYRIDIN-9-YL-4-(2-OXO-2,3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDIN-1-YL)PIPERIDINE-1-CARBOXYLATE SALT | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-29 | — | — | US | disclosed |
| US-8143403-B2 | CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| US-20120010402-A1 | CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2012-01-12 | — | — | US | disclosed |
| US-8044043-B2 | CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-25 | — | — | US | disclosed |
| US-8044043-B2 | CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-25 | — | — | US | disclosed |
| US-20110251223-A1 | CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-13 | — | — | US | disclosed |
| WO-2011046997-A1 | CGRP RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-21 | — | — | WO | disclosed |
| EP-2271640-A2 | PIPERIDINE DERIVATIVES AS CGRP RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009126530-A2 | CGRP RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-15 | — | — | WO | disclosed |
| US-20090258866-A1 | CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-15 | — | — | US | disclosed |
| US-20090258866-A1 | CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010402-A1 | CGRP Receptor Antagonists | CALCRL, BDKRB2, CALCR | CALCRL 1/4885ADRB2 46/4885CYP3A4 3571/4885 |
| US-20130225636-A1 | N-(5S,6S,9R)-5-AMINO-6-(2,3-DIFLUOROPHENYL)-6,7,8,9-TETRAHYDRO-5H-CYCLOHEPTA[B]PYRIDIN-9-YL-4-(2-OXO-2,3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDIN-1-YL)PIPERIDINE-1-CARBOXYLATE SALT | HTR5A, PTGIS, HRH4 | CALCRL 7/4885ADRB2 85/4885CYP3A4 3272/4885 |
| US-20150099771-A1 | PYRIDINE CGRP RECEPTOR ANTAGONISTS | CALCRL, P2RX3, P2RY1 | CALCRL 1/4885ADRB2 394/4885CYP3A4 2602/4885 |
| US-20090258866-A1 | CGRP Receptor Antagonists | CALCRL, BDKRB2, CALCR | CALCRL 1/4885ADRB2 46/4885CYP3A4 3571/4885 |
| US-20110251223-A1 | CGRP Receptor Antagonists | CALCRL, BDKRB2, CALCR | CALCRL 1/4885ADRB2 44/4885CYP3A4 2984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.